• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    AU-007 Shows Anti-Tumor Activity in Advanced Solid Tumors at SITC

    BUSINESSWIRE

    Aulos Bioscience Presents Phase 2 Data for AU-007 at EORTC

    BUSINESSWIRE

    Aulos Bioscience Announces AU-007 Phase 2 Dose Selection

    BUSINESSWIRE

    Aulos To Present AU-007 Phase 2 Data At SITC Annual Meeting

    BUSINESSWIRE

    Aulos Au-007 Interim Positive: Phase 1/2 Data At Asco 2024

    BUSINESSWIRE

    Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo

    BUSINESSWIRE

    First Patient Dosed in Phase 2 Portion of Aulos’ Phase 1/2 Trial for AU-007

    BUSINESSWIRE

    New Phase 1 Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic

    BUSINESSWIRE

    Aulos Announces Presentation of Updated Safety and Efficacy Data From AU-007

    BUSINESSWIRE

    Aulos Raises $20M in Series A Extension Financing From Apple Tree Partners

    BUSINESSWIRE

    Inovio prunes headcount again; Aulos adds to Series A

    ENDPTS

    Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated

    BUSINESSWIRE

    Aulos Bioscience begins US subject dosing in solid tumours therapy trial

    CLINICAL TRIALS ARENA

    First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Trial of AU-007

    BUSINESSWIRE

    Aulos Presents Initial Data From First-in-Human Ph 1/2 Clinical Trial AU-007

    BUSINESSWIRE

    Aulos to Present Data From Ph1/2 Trial of IL-2 Therapeutic AU-007 at SITC

    BUSINESSWIRE

    Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of AU-007

    BUSINESSWIRE

    Aulos Bioscience Initiates PI/II Trial of AU-007 for Solid Tumors

    BUSINESSWIRE

    Aulos to Present First-in-Human Phase 1/2 Trial of AU-007 at ASCO

    BUSINESSWIRE

    Aulos obtains approval to start Phase I/II trial for solid tumour asset

    CLINICALTRIALSARENA

    Aulos to Present Preclinical Data on Computationally Evolved IL-2 hAb AU-007

    BUSINESSWIRE

    Aulos Bioscience Appoints Aron Knickerbocker as CEO

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.